ArticleMicroorganisms2020
Anti-Inflammatory and Gut Microbiota Modulatory Effect of
Article in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Preclinical evidence of probiotics in ulcerative colitis: a systematic review and network meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Fermentation Technology in Aquafeeds: A Review.Microorganisms · 2026Review
- Article
- Atopic dermatitis-alleviating effects of lactiplantibacillus plantarum LRCC5195 paraprobiotics through microbiome modulation and safety assessment via genomic characterization and in vitro analysis.Scientific reports · 2025Article
- Microbiota and inflammatory bowel disease: the dual effect mechanism of polysaccharide therapy.Frontiers in immunology · 2025Review
- Article
- MicroencapsulatedNutrients · 2023Article
- A Novel Probiotic-Based Oral Vaccine against SARS-CoV-2 Omicron Variant B.1.1.529.International journal of molecular sciences · 2023Article
- Anti-inflammatory and wound healing properties of lactic acid bacteria and its peptides.Folia microbiologica · 2023Review
- The Potential Therapeutic Role ofFoods (Basel, Switzerland) · 2023Article
- Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022.Frontiers in microbiology · 2023Review
- Effect of Microencapsulation Techniques on the Stress Resistance and Biological Activity of Bovine Lactoferricin-Lactoferrampin-EncodingFoods (Basel, Switzerland) · 2022Article
- Lactobacillus rhamnosus GG ameliorates DON-induced intestinal damage depending on the enrichment of beneficial bacteria in weaned piglets.Journal of animal science and biotechnology · 2022Article
- Association between intestinal microbiome and inflammatory bowel disease: Insights from bibliometric analysis.Computational and structural biotechnology journal · 2022Article
- Longitudinal Microbiome Analysis in a Dextran Sulfate Sodium-Induced Colitis Mouse Model.Microorganisms · 2021Article
- Metformin Exerts Anti-inflammatory and Mucus Barrier Protective Effects by Enriching Akkermansia muciniphila in Mice With Ulcerative Colitis.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a group of conditions involving chronic relapsing-remitting inflammation of the gastrointestinal tract with an unknown etiology. Although the cause-effect relationship between gut microbiota and IBD has not been clearly established, emerging evidence from experimental models supports the idea that gut microbes play a fundamental role in the pathogenesis of IBD. As microbiome-based therapeutics for IBD, the beneficial effects of probiotics have been found in animal colitis models and IBD patients. In this study, based on the dextran sulfate sodium (DSS)-induced colitis mouse model, we investigated Lactobacillus rhamnosus strain LDTM 7511 originating from Korean infant feces as a putative probiotic strain for IBD. The strain LDTM 7511 not only alleviated the release of inflammatory mediators, but also induced the transition of gut microbiota from dysbiotic conditions, exhibiting the opposite pattern in the abundance of DSS colitis-associated bacterial taxa to the DSS group. Our findings suggest that the strain LDTM 7511 has the potential to be used as a probiotic treatment for IBD patients in comparison to L. rhamnosus GG (ATCC 53103), which has been frequently used for IBD studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.